Nature’s “Silver Bullet” for Anticoagulation: Mechanism of Zymogen Protein C to Activated Protein C

Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 765)

Abstract

We have defined the Zymogen Protein C (ZPC) to Activated Protein C (APC) process as the “silver bullet” of blood anticoagulation. This definition suggests that the anticoagulation activity occurs when and where it is needed, resulting in local anticoagulation without enhanced bleeding. It is important for man to be able to manufacture an inexpensive ZPC product or to find a substitute drug to duplicate one of God’s natural anticoagulant/antithrombotic processes, in vivo, in human blood. After intense research and at great expense scientists have not been able to produce a safe anticoagulant. All products that are now being used can cause bleeding even if dosing is carefully monitored. In fact many professionals in the health care and the pharmaceutical industries define an anticoagulant as a drug that “does” cause bleeding. This results in a large financial burden that has been placed on the health care industry because of necessary emergency treatments for dangerous occurrences. In addition, many patients are dying annually due to internal and external bleeds created or enhanced by presently administered anticoagulants. Since there are no safe drugs available it is necessary to use the existing products when a medical condition calls for an anticoagulant. This paper will discuss the ZPC process and why its mechanistic design is one of nature’s unique defenses against unwanted blood clotting. The prevention and lysis of clots allows normal blood flow and therefore results in the required tissue oxygenation for cell function and survival. If clinical research is carried out with great care it could uncover other uses of ZPC that will allow safer medical procedures, in addition to its use with standard PC deficiency cases. An important example might be for some brain surgeries where the use of existing anticoagulants is unsafe because of potential bleeds. Clinical research could reveal an efficacious ZPC level (for instance, 125, 150, or 200% of normal) that would prevent dangerous clotting situations from occurring without unnecessary bleeding.

Keyword

Protein C 

Notes

Acknowledgments

The authors would like to express their appreciation to E. Eileen Thiessen for the preparation of the power point slide presentation and the production of this paper.

References

  1. 1.
    Bruley DF (2012) The history of ISOTT. In: Wolf M, Bucher HU, Rudin M et al (eds) Oxygen transport to tissue XXXIII, Adv Exp Med Biol, Springer, New York 737:1–9Google Scholar
  2. 2.
    Bruley DF (2008) ISOTT: roots, founding and beyond. In: Kang KA, Harrison DK, Bruley DF (eds) Oxygen transport to tissue XXIX, Adv Exp Med Biol. Springer, New York, 614:1–8Google Scholar
  3. 3.
    Goro FW (1948) Blood sludge. Life Mag 24(22):49–59Google Scholar
  4. 4.
    Thews G (1960) Oxygen diffusion in the brain. A contribution to the question of the oxygen supply of the organs. Pflugers Archiv 271:197–226CrossRefGoogle Scholar
  5. 5.
    Reneau DD, Bruley DF, Knisely MH (1967) A mathematical simulation of oxygen release, diffusion and consumption in the capillaries and tissue of the human brain. In: Hershey D (ed) Chemical engineering in medicine and biology. Plenum, New York, pp 135–241CrossRefGoogle Scholar
  6. 6.
    Artigue RS, Bruley DF (1983) The transport of oxygen, glucose, carbon dioxide and lactic acid in the human brain: mathematical models. In: Oxygen transport to tissue IV, Adv Exp Med Biol. Plenum 159:1–4Google Scholar
  7. 7.
    Bicher HI, Bruley DF, Knisely MH (1973) Anti-adhesive drugs and tissue oxygenation. In: Bruley DF, Bicher HI (eds) Adv Exp Med Biol. Plenum 37:657–667Google Scholar
  8. 8.
    Stenflo J (1976) Á new vitamin K-dependent protein. J Biol Chem 251:355–363PubMedGoogle Scholar
  9. 9.
    Mammen EF, Thomas WR, Seegers WH (1960) Activation of purified prothrombin to autoprothrombin II (platelet cofactors II or autoprothrombin IIA). Thromb Diath Haemorrh 5:218–249PubMedGoogle Scholar
  10. 10.
    Marcianik E (1972) Inhibitor of human blood coagulation elicited by thrombin. J Lab Clin Med 79:924–934Google Scholar
  11. 11.
    Seegers WH, Novoa E, Henry RL et al (1976) Relationship of “new” vitamin K-dependent Protein C and “old” autoprothrombin II-a. Thromb Res 8(5):543–552CrossRefPubMedGoogle Scholar
  12. 12.
    Kisiel W (1979) Human plasma protein C: isolation, characterization and mechanism of activation by a thrombin. J Clin Invest 4:761–769CrossRefGoogle Scholar
  13. 13.
    Esmon CT (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264(9):4743–4746PubMedGoogle Scholar
  14. 14.
    Fernlund P, Stenflo J (1982) Ámino acid sequence of the light chain of bovine protein C. J Biol Chem 257(20):12170–12179PubMedGoogle Scholar
  15. 15.
    Kisiel W, Carnfield WM, Ericsson LH et al (1977) Ánticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 16(26):5824–5831CrossRefPubMedGoogle Scholar
  16. 16.
    Clouse LH, Comp PC (1986) The regulation of hemostasis: the protein C system. N Engl J Med 314(20):1298–1304CrossRefPubMedGoogle Scholar
  17. 17.
    Bertina RM (1988) Protein C and related proteins: biochemical and clinical aspects (contemporary issues in haemostasis and thrombosis). Churchill Livingstone, New YorkGoogle Scholar
  18. 18.
    Colucci M (1984) Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkey. J Clin Invest 74:200–204CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Comp P, Esmon C (1981) Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 68(5):1221–1228CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gruber A, Griffin JH, Harker LA et al (1989) Inhibition of platelet-dependent thrombosis formation by human activated protein C in a primate model. Blood 73:639–642PubMedGoogle Scholar
  21. 21.
    Okijima K, Koga S, Kaji M et al (1990) Effect of protein C and activated protein C on coagulation and fibrinolysis on normal human subjects. Thromb Haemostasis 3:48–53Google Scholar
  22. 22.
    Sharma GR, Grinnell BW et al (2008) Activated protein C modulates chemokine response and tissue injury in experimental sepsis. In: Kang KA, Harrison DK, Bruley DF (eds) Oxygen transport to tissue XXIX, Adv Exp Med Biol 614:83–91Google Scholar
  23. 23.
    Bruley DF, Drohan WN (1990) Protein C and related anticoagulants. Advances in applied biotechnology series, volume 11. Gulf Publishing Company (Portfolio Publishing Company), Houston, TX.Google Scholar
  24. 24.
    Winslow R (1995) Increased use of blood-thinning drugs could prevent 40,000 strokes a year, Wall St. J Sep 8Google Scholar
  25. 25.
    Vukovich T, Auerger K, Weil J et al (1988) Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S. Br J Haematol 70(4):435–440CrossRefPubMedGoogle Scholar
  26. 26.
    Dreyfus M, Magny JF, Bridey F et al (1991) Treatment of homologous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 325(22):1565–1568CrossRefPubMedGoogle Scholar
  27. 27.
    Manco-Johnson M, Nuss R (1992) Protein C concentrate prevents peripartum thrombosis. Am J Hematol 40(1):69–70CrossRefPubMedGoogle Scholar
  28. 28.
    Marlar RA, Montgomery RR, Broakman AW (1989) Diagnosis and treatment of homozygous protein C deficiency Report of the working party on homozygous protein C deficiency of the subcommittee on protein C and protein S, International Committee on Thrombosis and Haemostasis. J Paediatrics 114(4 Pt 1):528–534CrossRefGoogle Scholar
  29. 29.
    Esmon CT (1990) Regulation of coagulation: the nature of the problem. In: Bruley DF, Drohan WN (eds) Protein C and related coagulants. Gulf, Houston, TX, p 3Google Scholar
  30. 30.
    Rapaport SI (1989) Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism, Blood 73(2):359–365PubMedGoogle Scholar
  31. 31.
    Rosenberg R, Marcum JA (1985) Heparin-like molecules and thrombotic disease. ASAIO J 8:215Google Scholar
  32. 32.
    Zushi M, Gomi K, Yamamoto S et al (1989) The last three consecutive epidermal growth ­factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 264(18):10351–10353PubMedGoogle Scholar
  33. 33.
    Walker FJ, Sexton PW, Esmon CT (1979) The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 571(2):333–342CrossRefPubMedGoogle Scholar
  34. 34.
    Fulcher CA, Gardiner JE, Griffin JH et al (1984) Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 63(2):486–489PubMedGoogle Scholar
  35. 35.
    Wu H, Bruley DF, Kang KA (1998) Protein C separation from human blood plasma Cohn fraction IV-1 using immobilized metal affinity chromatography. In: Hudetz AG, Bruley DF (eds) Oxygen transport to tissue XX, Adv Exp Med Biol, Plenum, New York, 454:697–704Google Scholar
  36. 36.
    Wu H, Bruley DF (1999) Homologous blood protein separation using immobilized metal affinity chromatography: protein c separation from prothrombin with application to the separation of factor IX and prothrombin. Biotechnol Prog 15(5):928–931CrossRefPubMedGoogle Scholar
  37. 37.
    Wu H, Bruley DF (2002) Chelator, metal ion and buffer studies for protein c separation. Comp Biochem Physiol A Mol Integr Physiol 132(1):213–220CrossRefPubMedGoogle Scholar
  38. 38.
    Tadepalli SS, Bruley DF, Kang KA et al (1997) Immobilized metal affinity chromatography process identification and scale-up for protein C production. In: Harrison DK, Delpy DT (eds) Oxygen transport to tissue XIX, Adv Exp Med Biol, Plenum, New York, 428:31–43Google Scholar
  39. 39.
    Grinnell B. Executive Director Biotechnology Research, Eli Lilly and CompanyGoogle Scholar
  40. 40.
    Velander WH, Johnson JL, Page RL et al (1992) High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci U S A 89(24):12003–12007CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Drohan WH, Wilkins TD, Lattime E et al (1994) A scalable method for the purification of recombinant human protein C from the milk of transgenic swine. Adv Bioprocess Eng, Kluwer Academic Publishers, Netherlands, 501–507Google Scholar
  42. 42.
    Bruley DF (2009) Zymogen protein c concentrate for safer heterozygote surgery, I am a guinea pig! Oxygen Transport to Tissue XXX, Adv Exp Med Biol, Springer, New York, 645:115–121Google Scholar
  43. 43.
    Bruley DF, Mears SC, Streiff MB (2010) Safer surgery using zymogen protein C Concentrate. In: Takahashi EJ, Bruley DF (eds) Oxygen transport to tissue XXXI, Adv Exp Med Biol, Springer, New York, 662:439–445Google Scholar
  44. 44.
    Bruley DF, Jagannath SB, Streiff MB (2011) Zymogen protein C to prevent clotting without bleeding during invasive medical procedures. In: LaManna JC, Puchowicz MA, Xu K et al. (eds) Oxygen transport to tissue XXXII, Adv Exp Med Biol, Springer, New York, 701:91–97Google Scholar
  45. 45.
    Thakkar SC, Streiff MB, Bruley DF et al (2010) Perioperative use of protein c concentrate for protein c deficiency in THA. Clinical orthopaedics and related research. Springer, NY, 468(7):1986–1990Google Scholar
  46. 46.
    Thiessen EE, Bruley DF (2003) Theoretical studies of IMAC interfacial phenomena for the purification of protein C. Oxygen transport to tissue XXV, Adv Exp Med Biol 540:183Google Scholar
  47. 47.
    Lee J, Thiessen EE, Bruley DF (2005) Anticoagulant/anti-inflammatory/antithrombotic protein C production-metal ion/protein interfacial interaction in immobilized metal affinity chromatography. Oxygen transport to tissue XXVI, Adv Exp Med Biol, Springer, NY, 566:381–387Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Synthesizer, Inc.Ellicott CityUSA
  2. 2.Division of Hematology, Department of Medicine, Anticoagulation Management ServiceJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations